News Medical on MSN2d
Study identifies best imaging methods for evaluating brain tumor response in melanoma patients
Raymond Y. Huang, MD, Ph.D., of the Department of Radiology at Brigham and Women's Hospital, is the corresponding author of a ...
Improving predictions about brain cancer outcomes with the right imaging criteria
A paper published in the Journal of Clinical Oncology, titled "Comparative Analysis of Intracranial Response Assessment ...
Hosted on MSN13d
BMY Gets EC Nod for Opdivo Plus Yervoy in First-Line Colorectal Cancer
Bristol Myers Squibb BMY announced that the European Commission has approved the combination of its blockbuster ...
FDA approves subcutaneous opdivo qvantig for most solid tumor indications
The U.S. Food and Drug Administration has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) injection for ...
The American Journal of Managed Care4d
FDA Approves First Subcutaneous Nivolumab Injection in Most Solid Tumors
FDA approves the first subcutaneous version of nivolumab, making PD-1 inhibitors available to new groups of patients.
Medical Xpress29d
Study finds increased survival with nivolumab plus ipilimumab vs. chemo for metastatic colorectal cancer
In this prespecified interim analysis, nivolumab plus ipilimumab was compared to chemotherapy. Overall, 303 patients who had not previously received systemic treatment were randomly assigned to ...
Pharmaceutical Technology7d
Ipilimumab + nivolumab by Bristol-Myers Squibb for Dedifferentiated Liposarcoma: Likelihood of Approval
Ipilimumab + nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Dedifferentiated Liposarcoma.
Bristol-Myers Squibb : FDA Approves Opdivo Qvantig For Subcutaneous Use In Adult Solid Tumors
Bristol Myers Squibb (BMY) announced Friday that the U.S. Food and Drug Administration has approved Opdivo Qvantig (nivolumab and ...
ascopubs.org18d
Real-World Outcomes in Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Nivolumab Plus Ipilimumab in the United States
LFSPROShiny: An Interactive R/Shiny App for Prediction and Visualization of Cancer Risks in Families With Deleterious Germline TP53 Mutations Among 187 patients identified (median follow-up, 22.4 ...
EurekAlert!4d
Research spotlight: Improving predictions about brain cancer outcomes with the right imaging criteria
Raymond Y. Huang, MD, Ph.D., of the Department of Radiology at Brigham and Women’s Hospital, is the corresponding author of a paper published in the Journal of Clinical Oncology, “Comparative Analysis ...